• / Free eNewsletters & Magazine
  • / My Account
Home>Amicus Therapeutic's Fabry treatment meets goals in late-stage trial

Amicus Therapeutic's Fabry treatment meets goals in late-stage trial

3party Content

Wed, 20 Aug 2014

By Michael Calia Amicus Therapeutics said Wednesday that a potential treatment for Fabry disease reached its primary endpoints in a late stage study. Shares of the company (FOLD) rose as much as 40% in premarket trading as the company said it would move forward with a procedure for submission of
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.